Resumen
Introducción. Se han descrito diferencias por género en la incidencia, la severidad y mortalidad asociadas al ataque cerebrovascular isquémico.
Objetivo. Describir el comportamiento de la respuesta inflamatoria en hombres y mujeres con un primer episodio de ACV isquémico.
Material y métodos. Se incluyeron 50 mujeres postmenopáusicas mayores de 45 años y 50 hombres mayores de 45 años con un primer episodio de ataque cerebrovascular isquémico. Se evaluaron y analizaron diferencias en
la presentación de síntomas, antecedentes, severidad, respuesta inflamatoria y mortalidad entre ambos géneros.
Resultados. Las mujeres tuvieron un promedio de edad mayor al momento de presentar un primer ataque cerebrovascular isquémico (72,9 ± 9,8 años vs. 69,7 ± 9,03 años; p= 0,09), sin diferencias en la severidad del evento (mediana NIHSS 10,4 ± 7,61 en mujeres vs. 10,46 ± 4,96 en hombres), con mayores niveles de colesterol total (216,39 ± 50,61 vs. 188,76 ± 49,56; p=0,007), LDL (140,40 ± 39,57 vs. 121,3 ± 45,36; p=0,032), HDL (44,69 ±
15,52 vs. 37,67 ± 12,23; p= 0,013), triglicéridos (158,03 ± 74,65 vs. 144,05 ± 55,64; p=0,291) y glicemia (142,77 ± 71,60 vs. 138,16 ± 115,75; p=0,826), menor respuesta inflamatoria evaluada por PCR ultrasensible, IL-6 y TNFalfa,
y mortalidad hospitalaria que los hombres (6,52% vs. 14%; p=0,231).
Conclusión. Se propone que las diferencias por género en el comportamiento del ACV isquémico observadas en este estudio podrían ser explicadas por la protección cardiovascular hormonal extendida o la existencia de factores
inherentes en las mujeres que les confieren un estado de protección ante un ACV isquémico.
Citas
ROGER VI, GO AS, LLOYD-JONES DM, BENJAMIN EJ, BERRY JD, BORDEN WB, ET AL. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation. 2012; 125: e68-87.
GOMES J, CHALELA J. Stroke in the Tropics. Sem Neurol. 2005; 25:290-99.
URIBE CS, JIMENEZ I, MORA MO, ARANA A, SÁNCHEZ JL, ZULUAGA I, ET AL. Epidemiología de las enfermedades cerebrovasculares en Sabaneta,
Colombia (1992-1993). Rev Neurol. 1997; 25:1008-12.
WHITE H, BODEN-ALBALA B, WANG C, ELKIND M, RUNDEK T, WRIGHT CB, ET AL. Ischemic Stroke Subtype Incidence Among Whites, Blacks, and Hispanics: The Northern Manhattan Study. Circulation. 2005; 111:1327-31.
TURTZO LC, MCCULLOUGH LD. Sex-specific responses to stroke. Future Neurol. 2010; 5: 47-59.
GARGANO JW, WEHNER S, REEVES M. Sex differences in acute stroke care in a statewide stroke registry. Stroke. 2008; 39:24–9.
GLADER EL, STEGMAYR B, NORRVING B, TERÉNT A, HULTER-ASBERG K, WESTER PO, ET AL. Sex differences in management and outcome after stroke: a Swedish national perspective. Stroke. 2003; 34:1970-75.
DI CARLO A, LAMASSA M, BALDERESCHI M, PRACUCCI G, BASILE AM, WOLFE CD, ET AL. Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe: data from a multicenter multinational hospital-based registry. Stroke. 2003; 34:1114 –19.
LABICHE LA, CHAN W, SALDIN KR, MORGENSTERN LB. Sex and acute stroke presentation. Ann Emerg Med. 2002; 40:453–60.
KAPRAL MK, FANG J, HILL MD, SILVER F, RICHARDS J, JAIGOBIN C, ET AL. Sex differences in stroke care and outcomes: results from the Registry of the Canadian Stroke Network. Stroke. 2005; 36:809–14.
ROQUER J, CAMPELLO AR, GOMIS M. Sex differences in first-ever acute stroke. Stroke. 2003; 34:1581–85.
PALNUM KD, ANDERSEN G, INGEMAN A, KROG BR, BARTELS P, JOHNSEN SP. Sex-related differences in quality of care and short-term mortality among patients with acute stroke in Denmark: a nationwide follow-up study. Stroke. 2009; 40:1134–39.
CHARLSON ME, POMPEI P, ALES KL, MCKENZIE CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987; 40:373-83.
LISABETH L, BUSHNELL C. Stroke risk in women: the role of menopause and hormone Therapy. Lancet Neurol. 2012; 11:82–91.
ROJAS JI, ZURRÚ MC, ROMANO M, PATRUCCO I, CRISTIANO E. Acute ischemic stroke and transient ischemic attack in the very old – risk factor profile and stroke subtype between patients older than 80 years and patients aged less than 80 years. Eur J Neurol. 2007; 14:895-99.
LLOYD-JONES D, ADAMS R, CARNETHON M, DE SIMONE G, PERGUSON TB, FLEGAL K, ET AL. Heart disease and stroke statistics – 2009 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation. 2009; 119:480–86.
PETREA RE, BEISER AS, SESHADRI S, KELLY-HAYES M, KASE CS, WOLF PA. Gender differences in stroke incidence and poststroke disability in the Framingham Heart Study. Stroke. 2009; 40:1032–37.
ROTHWELL PM, COULL AJ, SILVER LE, FAIRHEAD JF, GIDES MF, LOVELOCK CE, ET AL. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet. 2005; 366:1773–83.
STUART-SHOR EM, WELLENIUS GA, DELLOIACONO DM, MITTLEMAN MA. Gender differences in presenting and prodromal stroke symptoms. Stroke. 2009; 40:1121–26.
SMITH DB, MURPHYS P, SANTOS P, PHILLIPS M, WILDE M. Gender differences in the Colorado Stroke Registry. Stroke. 2009; 40:1078 –81.
GALL SL, DONNAN G, DEWEY HM, MACDONELL R, STURM J, GILLIAN A, ET AL. Sex differences in presentation, severity, and management of stroke in a populationbased study. Neurology. 2010; 74:975–81.
TURHAN N, ATALAY A, MUDERRISOGLU H. Predictors of functional outcome in first-ever ischemic stroke: a special interest to ischemic subtypes, comorbidity and age. NeuroRehabilitation. 2009; 24:321-6.
BUSHNELL CD, LEE J, DUNCAN PW, NEWBY LK, GOLDSTEIN LB. Impact of comorbidities on ischemic stroke outcomes in women. Stroke. 2008; 39:2138-40.
SOLBERG OG, DAHL M, MOWINCKEL P, STAVEM K. Derivation and validation of a simple risk score for predicting 1-year mortality in stroke. J Neurol. 2007; 254:1376-83.
FISCHER U, ARNOLD M, NEDELTCHEV K, SCHOENENBERG RA, KAPPELER I, HOLLINGER P, ET AL. Impact of comorbidity on ischemic stroke outcome. Acta Neurol Scand. 2006; 113:108-13.
GOLDSTEIN LB, SAMSA GP, MATCHAR DB, HORNER RD. Charlson Index comorbidity adjustment for ischemic stroke outcome studies. Stroke. 2004; 35:1941-45.
BARRET KM, BROTT TG, BROWN RD JR, FRANKEL MR, WORRAL BB, SILLIMAN SI, ET AL. Sex differences in stroke severity, symptoms, and deficits after first-ever ischemic stroke. J Stroke Cerebrovasc Dis. 2007; 16:34–39.
KAPRAL MK, FANG J, HILL MD, SILVER F, RICHARDS J, JAIGOBIN C, ET AL. Sex differences in stroke care and outcomes: results from the Registry of the Canadian Stroke Network. Stroke. 2005; 36:809–14.
SILVA FA, ZARRUK JG, SILVA SY, BERNAL O, RUEDA-CLAUSEN F, PRADILLA G, ET AL. Estudio de correlación entre marcadores de inflamación y grosor íntima media carotídeo, en pacientes con ataque cerebrovascular isquémico. Acta Neurol . (Colombia) 2006; 22:3-11.
BAUTISTA LE, LOPEZ-JARAMILLO P, VERA LM, CASAS JP, OTERO AP, GUARACAO AI. Is C-reactive protein an independent risk factor for essential hypertension?. J Hyperten. 2001; 19:857-61.
RITZEL RM, CAPOZZI LA, MCCULLOUGH LD, Sex, stroke, and inflammation: The potential for estrogen-mediated immunoprotection in stroke. Horm Behav. 2012. [In press].
STRAUB RH. The complex role of estrogens in inflammation. Endocr Rev. 2007; 28: 521–74.
SUZUKI S, BROWN CM, WISE PM, Neuroprotective effects of estrogens following ischemic stroke. Front Neuroendocrinol. 2009; 30:201–11.
WEN Y, YANG S, LIU R, PEREZ E, YI KD, KOULEN P, ET AL. Estrogen attenuates nuclear factor-kappa B activation induced by transient cerebral ischemia. Brain Res. 2004; 1008:147–54.
KOERNER IP, ZHANG W, CHENG J, PARKER S, HURN PD, ALKAYED NJ. Soluble epoxide hydrolase: regulation by estrogen and role in the inflammatory response to cerebral ischemia. Front Biosci. 2008; 13: 2833–41.
OSPINA JA, BREVING HN, KRAUSE DN, DUCKLES SP. Estrogen suppresses IL-1beta-mediated induction of COX-2 pathway in rat cerebral blood vessels. Am. J Physiol Heart Circ Physiol. 2004; 286:2010–19.
GRODSTEIN F, MANSON JE, COLDITZ GA, WILLET WC, SPEIZER FE, STAMPFER MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000; 133:933–41.
GRODSTEIN F, MANSON JE, STAMPFER MJ. Postmenopausal hormone use and secondary prevention of coronary events in the Nurse’s Health Study. A prospective, observational study. Ann Intern Med. 2001; 135:1–8.
MATHEWS KA, KULLER LH, SUTTON-TYRRELL K, CHANG Y-F.Changes in cardiovascular risk factors during the perimenopause and postmenopause and carotid artery atherosclerosis in healthy women. Stroke. 2001; 32:1104–11.
LI H, PIN S, ZENG Z, WANG MM, ANDREASSON KA, MCCULLOUGH LD, Sex differences in cell death. Ann Neurol. 2005; 58:317–21.
HEYER A, HASSELBLATT M, VON AHSEN N, HAFNER H, SIREN AL, EHRENREICH H. In vitro gender differences in neuronal survival on hypoxia and in 17β-estradiol-mediated neuroprotection. J Cereb Blood Flow Metab. 2005; 25:427–30.
LIU M, HURN PD, ROSELLI CE, ALKAYED NJ. Role of p450 aromatase in sex-specific astrocytic cell death. J. Cereb. Blood Flow Metab. 2007; 27:135–41.
DU I, BAYIR H, LAI Y, ZHANG X, KOCHANEK PM, WATKINS SC, ET AL. Innate gender-based proclivity in response to cytotoxicity and programmed cell death pathway. J Biol Chem. 2004; 279:38563–70.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.